Active substanceHydrochlorothiazide + EnalaprilHydrochlorothiazide + Enalapril
Similar drugsTo uncover
  • Berlipril® plus
    pills inwards 
    BERLIN-PHARMA, CJSC     Russia
  • Co-Renitek®
    pills inwards 
       
  • Renipril® GT
    pills inwards 
  • Enalapril NL
    pills inwards 
    OZONE, LLC     Russia
  • Enalapril NL 20
    pills inwards 
    OZONE, LLC     Russia
  • Enalapril-Acry® H
    pills inwards 
    AKRIKHIN HFK, JSC     Russia
  • Enalapril-Acry® NL
    pills inwards 
    AKRIKHIN HFK, JSC     Russia
  • TEVA, LLC     Russia
  • TEVA, LLC     Russia
  • Enam® H
    pills inwards 
  • Enap®-HL
    pills inwards 
  • Enap®-HL 20
    pills inwards 
  • Enap®-H
    pills inwards 
  • Enafarm®-H
    pills inwards 
  • Dosage form: & nbspPills.
    Composition:

    1 tablet contains: active substances: enalapril maleate 10.0 mg, hydrochlorothiazide 25.0 mg; Excipients: lactose monohydrate 138.0 mg, corn starch 6.0 mg, pregelatinized starch 16.0 mg, sodium hydrogen carbonate 7.8 mg, magnesium stearate 1.0 mg.

    Description:Round tablets of biconvex form of white with separating risk and engraving "EL" and "10" on one side.
    Pharmacotherapeutic group:hypotensive combined agent (angiotensin-converting enzyme inhibitor + diuretic).
    ATX: & nbsp

    C.09.B.A.02   Enalapril in combination with diuretics

    Pharmacodynamics:

    Combined antihypertensive drug, which includes enalapril an angiotensin-converting enzyme (ACE) inhibitor; and hydrochlorothiazide - Thiazide diuretic. Has antihypertensive and diuretic effect.

    Enalapril catalyzes the conversion of angiotensin I to pressor substance angiotensin II. After suction enalapril is converted by hydrolysis into enalaprilate, which inhibits ACE. Inhibition of ACE leads to a decrease in angiotensin concentration II in blood plasma, which leads to an increase in renin activity of blood plasma (due to elimination of the reverse negative reaction to changes in renin production) and a decrease in the secretion of aldosterone. ACE is identical, the enzyme kininase II, so enalapril can also block the destruction of bradykinin, which has a vasodilating effect.The significance of this mechanism in the therapeutic action of enalapril requires refinement. Although enalapril reduces blood pressure (BP) by suppression, the renin-angiotensin-aldosterone system (RAAS), which plays an important role in the regulation of blood pressure, enalapril reduces BP even in patients with hypertension with low renin concentration. Reduction of blood pressure is accompanied by a decrease in the total peripheral vascular resistance (OPSS), a slight increase in cardiac output, and no changes or slight changes in the heart rate (heart rate). As a result of enalapril, renal blood flow increases, the glomerular filtration rate remains unchanged. However, in patients with initially reduced glomerular filtration, its rate usually increases.

    Hypotensive therapy with enalapril leads to a significant regression of left ventricular hypertrophy and preservation of left ventricular systolic function. Therapy with enalapril is accompanied by a favorable effect on the ratio of fractions of lipoproteins and the absence of influence or favorable effect on the content of total cholesterol.The use of enalapril in patients with hypertension leads to a decrease in blood pressure in both the "standing" and "lying" positions without a significant increase in heart rate.

    Symptomatic orthostatic arterial hypotension develops rarely. In some patients, achieving an optimal BP reduction may require several weeks of therapy. Interruption of enalapril therapy does not cause a sharp rise in blood pressure.

    Effective inhibition of ACE activity usually develops 2-4 hours after a single dose of enalapril inside. The onset of antihypertensive action develops within 1 hour, the maximum decrease in blood pressure is observed 4-6 hours after taking the drug. The duration of action depends on the dose. However, when used in the recommended doses, the antihypertensive effect and hemodynamic effects persist for 24 hours.

    Hydrochlorothiazide has a diuretic and antihypertensive effect, increases the activity of renin, stimulates the secretion of aldosterone, increases the concentration of angiotensin II, reduces the reabsorption of sodium and chlorine ions, to a lesser extent - potassium ions and hydrocarbonates in the proximal tubule of the kidneys, increases the excretion of magnesium ions and reduces - calcium ions, urinary acid.Inhibits the reactivity of the vascular wall with respect to the vasoconstrictive effects of mediators in connection with a decrease in the concentration of sodium ions in the cytoplasm of myocyte vessels, reduces the volume of circulating blood (BCC), reduces blood pressure. Diuretic effect occurs after 2 hours, reaches a maximum after 4 hours and persists for 12 hours.

    The use of a combination of enalapril and hydrochlorothiazide results in more marked decrease in blood pressure in comparison with monotherapy with enalapril or hydrochlorothiazide and allows to keep antihypertensive effect for at least 24 hours. Enalapril reduces the loss of potassium ions caused by the use of hydrochlorothiazide.

    Pharmacokinetics:

    Enalapril

    Suction. After oral administration, it is rapidly absorbed. Absorption is approximately 60% and is not dependent on food intake. The maximum concentration (CmOh) in the blood serum is observed within 1 h after administration. After absorption, it rapidly hydrolyses to form an active metabolite of enalaprilate, an ACE inhibitor.

    FROMmOh is observed 3-4 hours after taking the dose inside.

    Distribution. 50-60% binds to blood plasma proteins.The constant concentration of enalaprilat in the serum is reached approximately on the 4th day. It penetrates the hematoplacental barrier and is excreted in breast milk.

    Metabolism and excretion. After suction enalapril is converted by hydrolysis into enalaprilate, there are no data on other significant metabolic pathways. It is excreted mainly by the kidneys. The main metabolites, determined in urine, are enalaprilate, which is approximately 40% of the dose, and unchanged enalapril. The concentration curve of enalaprilate in blood plasma has a long final phase, which is apparently due to its binding to the ACE. In patients with normal renal function, the equilibrium concentration of enalaprilat is reached on the 4th day after the start of enalapril. The half-life (T1/2) enalaprilata with course use enalapril inside is 11h.

    Hydrochlorothiazide

    Suction. After ingestion, 60-80% of the dose is absorbed from the gastrointestinal tract (GIT). Time to reach CmOh in the blood plasma -1,5-3 h.

    Distribution. 40-60% binds to blood plasma proteins. It penetrates the hematoplacental barrier and is excreted in breast milk.

    Metabolism and distribution. Not exposed to metabolism.It penetrates the hematoplacental barrier and is excreted in breast milk, does not penetrate the blood-brain barrier.

    Excretion. T1/2 differs in different patients and can be from 6 to 25 hours. Kidney clearance is 90% of the total clearance, 95% is unchanged.

    In renal and heart failure, as well as in elderly patients, renal clearance of hydrochlorothiazide is reduced, T1/2 and CmOh increased.

    Indications:
    Arterial hypertension (patients who require combined therapy).
    Contraindications:

    Hypersensitivity to enalapril, hydrochlorothiazide, other derivatives of sulfonamide and other components of the drug; angioedema in history, associated with the administration of ACE inhibitors, as well as hereditary or idiopathic angioedema; anuria; renal failure of severe degree (QC less than 30 ml / min); hepatic failure of severe degree; simultaneous use with aliskiren or aliskiren-containing drugs in patients with diabetes mellitus and / or renal dysfunction (GFR less than 60 ml / min / 1.73 m2) (cm.Interaction with other medicinal products); age to 18 years; lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome; pregnancy and breastfeeding.

    Carefully:Violation of the water-electrolyte balance (decrease in the volume of circulating blood (bcc), hyponatremia, hypochlorismic alkalosis, hypomagnesemia, hypokalemia), which can develop against a background of intercurrent diarrhea or vomiting, in patients observing a diet with restriction of table salt during dialysis; aortic or mitral stenosis; hypertrophic obstructive cardiomyopathy (GOKMP); cerebrovascular diseases, ischemic heart disease (IHD), systemic connective tissue diseases (including systemic lupus erythematosus, scleroderma), oppression of bone marrow hematopoiesis, immunosuppressive therapy, diabetes mellitus, bilateral stenosis of the renal arteries, stenosis of the single kidney artery, condition after kidney transplantation, treatment with allopurinol or procainamide; hyperkalaemia, simultaneous use with potassium-sparing substitutes for table salt and lithium preparations;low-density lipoprotein (LDL) -pheresis with dextran sulfate; during desensitization with the allergen from the Hymenoptera venom; in patients on dialysis using high-flow membranes (such as AN69®); in patients after major surgery or in general anesthesia; in patients of the Negroid race.
    Pregnancy and lactation:
    The use of the drug may cause the disease or death of the fetus or newborn. It is not recommended to use the drug Enalapril / Hydrochlorothiazide-Teva during pregnancy. If pregnancy is established, use Enalapril / Hydrochlorothiazide-Teva immediately and consult a doctor. The results of the epidemiological study of newborns whose mothers took ACE inhibitors in the first trimester of pregnancy showed an increased risk of developing serious congenital malformations compared to newborns whose mothers did not take ACE inhibitors during the first trimester of pregnancy. The use of ACE inhibitors in the II and III trimesters of pregnancy was accompanied by a negative impact on the fetus and the newborn, including the development of arterial hypotension, renal failure, hyperkalemia and / or hypoplasia of the skull bones.In addition, it was reported about the development of 'prematurity, delay in utero development and non-spread of the ductus arteriosus. A clear connection between the development of these pathological conditions and the mother's intake of ACE inhibitors has not been revealed. The development of oligohydramnion, possibly, is associated with a decrease in the function of the kidneys of the fetus. This complication can lead to limb contracture, deformation of the bones of the skull, including its facial part, and lung hypoplasia. The use of diuretics during pregnancy is not recommended because it can cause jaundice of the fetus and newborn, thrombocytopenia and possibly other unwanted reactions observed with the use of diuretics in adult patients. In those rare cases when the use of the drug during pregnancy is vital for the mother, the doctor should inform the patient about the potential risk to the fetus. In this case, a periodic ultrasound examination of the intra-amniotic space should be performed. When the oligohydramnion is detected, the drug is stopped, except when it is vitally important for the mother.The doctor should remember, and also inform the patient that the oligohydramnion can develop after irreversible damage to the fetus. If a decision is made to use ACE inhibitors already with the developed oligohydramnione, then, depending on the period of pregnancy, tests can be used to determine the functional state of the fetus (contractile stress test, non-stress test or fetal biophysical profile). Newborns whose mothers took the drug should be carefully monitored for the detection of arterial hypotension, oliguria, and hyperkalemia. In the case of development of oliguria, the attention of the doctor should be directed to the maintenance of blood pressure and renal perfusion.
    Enalapril and hydrochlorothiazide excreted in breast milk. If you need to use Enalapril / Hydrochlorothiazide-Teva during lactation, breastfeeding should be discontinued.
    Dosing and Administration:

    Inside, 1 tablet 10 mg + 25 mg once a day, at the same time of the day, regardless of food intake. Before using Enalapril / Hydrochlorothiazide-Teva, diuretics should be discontinued.

    In patients with severe renal insufficiency (CC less than 30 ml / min) The drug Enalapril / Hydrochlorothiazide-Teva is not used.

    In patients with mild and moderate renal insufficiency (KC more than 30 ml / min) a drug Enalapril/ Hydrochlorothiazide-Teva can be used only after the stabilization of blood pressure on the background of treatment with drugs enalapril and hydrochlorothiazide in separate dosage forms and the selection of their doses. The recommended initial dose of Enalapril / Hydrochlorothiazide-Teva is 1/2 tablets 10 mg + 25 mg once a day. It should be regularly (every 2 months) to monitor the potassium content and the concentration of creatinine.

    In elderly patients the recommended initial dose is 1/2 tablets 10 mg + 25 mg once a day.

    Side effects:

    In clinical studies of the enalapril / hydrochlorothiazide combination, no adverse events specific to this combination drug were observed. Undesirable effects were limited to those reported earlier with enalapril and / or hydrochlorothiazide alone.

    The incidence of side effects is classified according to the recommendations of the World Health Organization: very often - at least 10%; often - not less than 1%, but less than 10%; infrequently - not less than 0,1%,but less than 1%; rarely - not less than 0.01%, but less than 0.1%; very rarely - 0.01%, including individual reports.

    Enalapril

    From the side of the blood and lymphatic system: rarely - reduction of hemoglobin, decrease in hematocrit; very rarely - oppression of bone marrow function, anemia, thrombocytopenia, leukopenia, neutropenia and agranulocytosis, hemolytic anemia, lymphadenopathy, eosinophilia.

    From the endocrine system: rarely - the syndrome of inadequate secretion of antidiuretic hormone.

    From the nervous system: often - headache, dizziness, fainting; infrequently - insomnia, anxiety, panic, confusion, depression, sleep disturbance, "nightmarish" dreams, drowsiness; rarely - memory impairment, paresthesia, peripheral neuropathy, tremor, migraine, confusion.

    From the side of the organ of vision: rarely - visual impairment, conjunctivitis, decreased visual acuity, dryness and burning eyes.

    From the side of the hearing organ and labyrinthine disorders: infrequently - vertigo, noise in the ears.

    From the cardiovascular system: often - marked decrease in blood pressure, orthostatic hypotension; infrequently - pain in the chest, stenocardia,atrioventricular blockade of II degree, cerebral blood flow disorder, myocardial infarction, palpitation, arrhythmia (atrial fibrillation, sinus bradycardia, tachycardia, ventricular fibrillation).

    On the part of the respiratory system, the organs of the thorax and the mediastinum: often - cough; infrequently - a rhinitis, zalozhennost a nose; very rarely - sinusitis, pharyngitis, laryngitis, sore throat, hoarseness, dyspnea, bronchitis, lung infiltrates, bronchospasm / bronchial asthma.

    From the digestive system: often - nausea, diarrhea; infrequently - abdominal pain, constipation; rarely - dryness of the oral mucosa, stomatitis, flatulence, vomiting, gastritis; very rarely - pancreatitis, intestinal obstruction.

    From the liver and bile ducts: infrequently - increased activity of "liver" transaminases, increased bilirubin concentration; very rarely - a violation of the liver, hepatitis hepatocellular or cholestatic, jaundice.

    From the skin and subcutaneous tissues: rarely - alopecia, psoriasis, dermatitis, dry skin; very rarely - pseudolymphoma, pemphigus.

    Allergic reactions: infrequently - a skin rash,itching; rarely - angioedema, swelling of the face, extremities, lips, tongue, vocal cords and / or larynx, dysphonia, urticaria; very rarely - toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, photosensitivity, intestinal edema.

    From the side of the musculoskeletal and connective tissue: often - muscle spasm, pain

    in the back, leg pain, myalgia; infrequently - pain in the hands, arthralgia, musculoskeletal pain,

    stiffness and swelling of the joints.

    From the urinary system: often - renal dysfunction; rarely - uremia, acute renal failure (ARF); very rarely - oliguria, anuria.

    On the part of the reproductive system: infrequently - impotence; rarely - gynecomastia.

    Other: often - asthenia, fatigue, hyperkalemia; infrequent - increased body temperature, a slight increase in the concentration of urea and creatinine, hyperkalemia; rarely - hyponatremia; very rarely - hyperglycemia, epistaxis, vasculitis, the phenomenon of Raynaud, "tides" of blood to the skin of the face; individual reports describe a symptom complex that may include fever, myalgia and arthralgia, serositis,vasculitis, an increase in the rate of erythrocyte sedimentation, leukocytosis and eosinophilia, a skin rash, a positive test for antinuclear antibodies.

    Hydrochlorothiazide

    From the side of the blood and lymphatic system: rarely - neutropenia and agranulocytosis, thrombocytopenia, aplastic anemia, hemolytic anemia, leukopenia, oppression of bone marrow function.

    From the side of metabolism and nutrition: infrequently - anorexia, hyperglycemia, hyperuricemia, hypokalemia, hyponatremia, increased cholesterol and triglycerides, gout.

    From the nervous system: often - depression, sleep disturbance; infrequently - insomnia, paresthesia, dizziness.

    From the side of the organ of vision: rarely - transient visual impairment, xantopsy.

    From the organ of hearing: rarely - vertigo.

    From the cardiovascular system: rarely - orthostatic hypotension.

    From the respiratory system, chest and mediastinum: infrequently - respiratory distress syndrome, pneumonitis, pulmonary edema.

    From the digestive system: rarely - sialadenitis, constipation, diarrhea, irritation of the gastrointestinal mucosa; very rarely - pancreatitis.

    From the liver and bile ducts: infrequently, jaundice (intrahepatic cholestasis).

    Allergic reactions: rarely - photosensitivity; very rarely - hives, toxic epidermal necrolysis, Lyell's syndrome.

    From the side of the musculoskeletal and connective tissue: infrequently - muscular spasm.

    From the urinary system: infrequently - glucosuria, interstitial nephritis, renal failure.

    Other: infrequently - fever, hyperkalemia, vasculitis.

    Overdose:

    Symptoms: marked decrease in blood pressure, collapse, water-electrolyte disorders, increased diuresis, renal failure, cough, palpitation, tachycardia, bradycardia, heart rhythm disturbances, dizziness, anxiety, confusion, convulsions, paresis.

    Treatment: in mild cases, induction of vomiting, gastric lavage, intake of activated charcoal. At a marked decrease in blood pressure, the patient is placed on his back, on a horizontal surface with a low headboard, his legs are raised, intravenously (intravenously) injected 9% solution of sodium chloride and / or plasma-substituting solutions.If necessary, hemodialysis is carried out (the rate of excretion of enalaprilate is 62 ml / min). The specific antidote is unknown.

    Interaction:
    With the simultaneous use of enalapril with diuretics that cause the loss of potassium ions (thiazides or looped diuretics), the symptoms of hypokalemia can be leveled. The potassium content in the serum usually remains within the normal range.
    ACE inhibitors and diuretics can reduce renal clearance of lithium and increase the risk of its toxic effects. It is not recommended simultaneous use of enalapril / hydrochlorothiazide and lithium preparations.
    In some cases, the use of non-steroidal anti-inflammatory drugs drugs (NSAIDs), including cyclooxygenase-2 inhibitors (COX-2), can reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics and other antihypertensive agents, including ACE inhibitors.
    In patients with impaired renal function that take NSAIDs, including C0G-2 inhibitors, ACE inhibitor therapy, including enalapril, or angiotensin II receptor antagonists (APA), may cause further impairment of kidney function, including acute kidney failure, which is usually reversible .
    Simultaneous use of enalapril with beta-blockers, methyldopa or blockers of "slow" calcium channels increases the severity of the antihypertensive effect.
    Simultaneous use of enalapril with alpha, beta-adrenoblockers and ganglion blockers should be carried out under the supervision of a doctor.
    Simultaneous use of enalapril / hydrochlorothiazide with nitroglycerin, other
    nitro drugs or other vasodilators enhances the antihypertensive effect. Double blockade of RAAS with the use of angiotensin II receptor antagonists (APA II), ACE inhibitors or aliskiren (renin inhibitor) is associated with an increased risk of arterial hypotension, syncope, hyperkalemia and renal dysfunction (including acute renal failure) compared with monotherapy. Regular monitoring of blood pressure, kidney function and electrolyte content in the blood in patients taking simultaneously

    enalapril / hydrochlorothiazide and other drugs that affect RAAS. Enalapril / hydrochlorothiazide should not be used concomitantly with aliskiren or aliskirenosodjashimi drugs in patients with diabetes mellitus and / or renal dysfunction (GFR less than 60 ml / min / 1.73 m2).Simultaneous use of ACE inhibitors, including enalapril, with potassium-sparing diuretics (spironolactone, triamterene, amiloride, eplerenone), potassium-containing additives or potassium salts, including those in patients with impaired nephritic function or diabetes, can lead to an increase in serum potassium. With the simultaneous use of ACE inhibitors, including enalapril, with tricyclic antidepressants and, baclofen, amifostine, the risk of a sudden drop in blood pressure increases. With simultaneous use of ACE inhibitors, including enalapril, with preparations of gold (sodium aurotomy malate) it is possible to develop nitrate-like reactions (headache that usually occurs at the beginning of treatment, tachycardia, orthostatic hypotension, manifested by dizziness, weakness and even short-term loss of consciousness).
    Sympathomimetics can reduce the antihypertensive effect of ACE inhibitors. including enalapril. With simultaneous use of ACE inhibitors. including enalapril, with other antihypertensive agents an additive effect is observed.With the simultaneous use of ACE inhibitors, including enalapril, with insulin and other hypoglycemic agents for oral administration, the risk of hypoglycemia increases, especially in patients with renal insufficiency. With the simultaneous use of ACE inhibitors, including enalapril, with allopurinol, cytostatics, procainamide, immunosuppressive drugs, their myelosuppressive effect is increased and the risk of developing renal failure increases.
    With simultaneous use of ACE inhibitors, including enalapril, with cyclosporine, lovastatin, the risk of renal dysfunction and the development of hyperkalemia are increased.
    According to reports rifampicin and fluconazole reduce the concentration of the active metabolite of enalapril, the clinical significance of this interaction has not been studied.
    The simultaneous use of hydrochlorothiazide with glucocorticosteroids (GCS), corticotropin, carbenoxolone, amphotericin B, trimethoprim may lead to a marked decrease in the electrolyte content, in particular, can cause hypokalemia.
    Simultaneous use of hydrochlorothiazide with calcium preparations can cause hypercalcemia. This should be taken into account also when examining the function of parathyroid glands.
    With the simultaneous use of thiazide diuretics, including hydrochlorothiazide, with cardiac glycosides, because of the possible development of hypocalysis, the likelihood of the toxic effect of cardiac glycosides, in particular, arrhythmias, increases.
    Anion exchange resins, as well as colestramine or colestipol in single doses bind hydrochlorothiazide and reduce its absorption from the digestive tract by 85% and 43%, respectively.
    It is possible to enhance the action of nondepolarizing muscle relaxants (tubocurarine) against hydrochlorothiazide. With simultaneous use with atropine, biperidenom bioavailability of thiazide diuretics, including hydrochlorothiazide, due to decreased gastrointestinal motility and gastric emptying rate can increase.
    The simultaneous use of thiazide diuretics, including hydrochlorothiazide, with quinidine, disopyramide, amiodarone, sotalol, ibutilide, chlorpromazine, haloperidol, sulpiride, erythromycin, pentamidine, terfenadine can cause hypokalemia and thereby cause the development of pirouette type arrhythmias. Individual cases of development of hemolytic anemia with simultaneous use of thiazide diuretics and methyldopa have been reported.
    With the simultaneous use of thiazide diuretics, including hydrochlorothiazide, with carbamazepine, there is a risk of developing hyponatremia.
    With the development of dehydration against the background of the use of thiazide diuretics, including hydrochlorothiazide, there is a possibility of acute renal failure, especially with simultaneous use with iodine preparations. Thiazide diuretics, including hydrochlorothiazide, can enhance the toxic effects of salicylates on the central nervous system when used in high doses.
    With the simultaneous use of thiazide diuretics, including hydrochlorothiazide, with barbiturates, opioid analgesics, ethanol, an increased risk of developing orthostatic hypotension is possible.
    In clinical studies of pharmacokinetics, there was no clinically significant enalapril / hydrochlorothiazide interaction with warfarin, cimetidine, phenobarbital, ketoconazole, and erythromycin.

    Special instructions:
    The drug Enalapril / Hydrochlorothiazide-Teva, containing enalapril 10 mg and hydrochlorothiazide 25 mg, is not used for the initial treatment of hypertension.This combination of doses can be used in case of inefficiency of monotherapy with enalapril, and also when stabilization of blood pressure has been achieved while using enalapril and hydrochlorothiazide in separate dosage forms in doses that are proportional to the doses of these active substances in the Enalanryl / hydrochlorothiazide-Teva preparation. During treatment with Enalapril / Hydrochlorothiazide-Teva, as with any antihypertensive therapy, there may be a marked decrease in blood pressure. Patients should be examined for the purpose of identifying clinical signs of a disturbance of the water-electrolyte balance, i.e. dehydration of the body, hyponatremia, hypochloraemic alkalosis, hypomagnesemia or hypokalemia that may occur as a result of episodes of diarrhea or vomiting, as a result of diuretic therapy, while limiting intake of table salt. Treatment patients drug
    Enalapril / hydrochlorothiazide-Teva should be administered under medical supervision and regular monitoring of water-electrolyte blood composition.
    Care should be taken when doing physical exercises or in hot weather (the risk of dehydration and a marked decrease in blood pressurebecause of the decrease in bcc).
    Transient arterial hypotension is not a contraindication for continuing treatment with Enalapril / Hydrochlorothiazide-Teva after stabilization of blood pressure. In the case of a re-expressed decrease in blood pressure should reduce the dose or cancel the drug Enalapril / Hydrochlorothiazide-Teva. With the development of a pronounced decrease in blood pressure, the patient is placed on his back, on a horizontal surface with a low headboard, his legs are raised, if necessary, 0.9% sodium chloride solution and / or plasma-substituting solutions are injected into /. With caution, use Enalapril / Hydrochlorothiazide-Teva in patients with ischemic heart disease, CHF and cerebrovascular diseases, a marked decrease in blood pressure can lead to the development of myocardial infarction, stroke, or impaired renal function.
    As with other medications with vasodilator action, caution should be exercised in patients with aortic and mitral stenosis or GOKMP with Enalapril / Hydrochlorothiazide-Teva. The sudden withdrawal of Enalapril / Hydrochlorothiazide-Teva does not lead to a withdrawal syndrome.
    Before surgery (including dental surgery), it is necessary to alert the surgeon / anesthesiologist about the use of ACE inhibitors, including Enalapril / Hydrochlorothiazide-Teva. The drug Enalapril / Hydrochlorothiazide-Teva should be taken with mild and moderate renal failure (QC more than 30 ml / min) only if the dosage of enalapril and hydrochlorothiazide medications has already been selected in separate dosage forms. In patients with bilateral renal artery stenosis or stenosis of the artery of a single kidney during treatment with ACE inhibitors, an insignificant and transient increase in serum urea and creatinine levels may occur. In such cases, treatment with Enalapril / Hydrochlorothiazide-Teva should be discontinued. In the future, it is possible to resume therapy with Enalapril / Hydrochlorothiazide-Teva in reduced doses or the use of individual dosage forms of drugs enalapril and hydrochlorothiazide. Increase in the concentration of creatinine and urea in the blood plasma against the background of treatment with ACE inhibitors in patients with hypertension without diseasekidney is also a signal to cancel the drug Enalapril / Hydrochlorothiazide-Teva and revision of the treatment regimen of hypertension.
    Simultaneous use of ACE inhibitors, ARA II or aliskiren increases the risk of hypotension, hyperkalemia and renal dysfunction (including acute renal failure). Double blockade of RAAS with the use of ACE inhibitors, APA II or aliskiren is not recommended (see section "Interaction with other drugs").
    If a double blockade of RAAS is considered absolutely necessary, the treatment should only take place under the supervision of specialists and should be accompanied by careful and frequent monitoring of kidney function, electrolyte content and blood pressure. ACE inhibitors and ARA II should not be used simultaneously in patients with diabetic nephropathy. When ACE inhibitors are used in renovascular hypertension, there is also a high risk of a marked decrease in blood pressure, so treatment in such patients begins with a low dose of Enalapril / Hydrochlorothiazide-Teva under the supervision of a doctor.ACE inhibitors should be used with caution in patients with impaired hepatic function or with progressive liver diseases, since even small disturbances of the water-electrolyte balance can lead to the development of hepatic coma.
    There are reports that ACE inhibitors were the cause of the development of the symptom complex, which began with cholestatic jaundice and quickly progressed to liver necrosis (in some cases with lethal outcome). The drug Enalanril / Hydrochlorothiazide-Teva should be discontinued if jaundice appeared during treatment or the activity of "liver" enzymes increased.
    In the treatment of ACE inhibitors, rare cases of angioedema edema of the face, extremities, lips, tongue, vocal folds and / or larynx have been described that can lead to airway obstruction, especially in patients undergoing surgical procedures on respiratory organs. There are rare reports of death in connection with angioedema, accompanied by edema of the larynx or edema of the tongue. These reactions can occur at any stage of therapy.In such cases, it is necessary to immediately stop taking Enalapril / Hydrochlorothiazide-Teva and to carefully monitor the patient's condition in order to monitor and correct clinical symptoms. In representatives of the Negroid race, which used ACE inhibitors, angioedema appeared more often than in patients of other races. With a history of angioedema, not associated with the administration of ACE inhibitors, the risk of developing angioedema in patients with Enalapril / Hydrochlorothiazide-Teva is significantly increased. There are reports of life-threatening anaphylactic reactions in the background of treatment with ACE inhibitors that have arisen from the bites of Hymenoptera (for example, bees, wasps).
    In rare cases, life-threatening anaphylactic reactions developed in patients taking ACE inhibitors during LDL-apheresis with dextran sulfate. The use of high-flow dialysis membranes (such as AN69) increases the risk of developing an anaphylactic reaction with the use of ACE inhibitors during the hemodialysis procedure. Discontinuation of therapy with Enalapril / Hydrochlorothiazide-Teva in each of the cases of threat of anaphylactic reaction may prevent such reactions.
    On the background of therapy with ACE inhibitors, cough may appear. As a rule, it is a dry cough, has a permanent character and disappears after the cessation of treatment. Cough associated with the use of ACE inhibitors should be considered in the differential diagnosis of cough. Neutropenia / agranulocytosis, thrombocytopenia and anemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function, neutropenia is very rare. Neutropenia and agranulocytosis are reversible after discontinuation of ACE inhibitors. In patients with severe autoimmune systemic diseases of connective tissue (including systemic lupus erythematosus, scleroderma) against the background of treatment with ACE inhibitors, severe infectious diseases developed that are resistant to intensive antibiotic therapy. Use with caution the drug Enalapril / Hydrochlorothiazide-Teva in this category of patients. In patients with diabetes mellitus, who take hypoglycemic drugs for oral use or insulin, in the first month of treatment with ACE inhibitors, regular glycemic control should be performed.
    The use of thiazide diuretics, including hydrochlorothiazide, can cause a decrease in glucose tolerance and manifestation of latent diabetes mellitus.
    When application of Enalapril / Hydrochlorothiazide-Teva in patients with diabetes mellitus may need to adjust the dose of insulin or hypoglycemic drugs for oral use.
    Treatment with hydrochlorothiazide can reduce the excretion of calcium by the kidneys, and also cause a slight and transient increase in serum calcium. Expressed hypercalcemia may be a sign of latent hyperparathyroidism. The intake of Enalapril / Hydrochlorothiazide-Teva should be discontinued before the study of parathyroid function. In spite of the fact that hypokalemia can occur with the use of thiazide diuretics, simultaneous therapy with enalapril may reduce the severity of hypokalemia caused by the use of a diuretic. The risk of hypokalemia is increased in patients with cirrhosis of the liver, with forced diuresis, in patients who are simultaneously receiving SCS or corticotropin therapy. Hypokalemia can increase the toxic effect of cardiac glycosides.Before and during use preparation
    Enalapril / hydrochlorothiazide-Teva should regularly monitor the potassium content in the blood plasma.
    Therapy with hydrochlorothiazide can lead to giururicemia and / or gout in some patients. Enalapril can increase the excretion of uric acid in the nights and thereby weaken the hyperuricemic effect. It is necessary to carry out periodic monitoring of the concentration of uric acid in order to prevent exacerbation of the gout during treatment with the drug Enalapril / Hydrochlorothiazide-Teva.
    When application of Enalapril / Hydrochlorothiazide-Teva can be obtained in doping control in athletes, because it includes hydrochlorothiazide. As reported for other ACE inhibitors, enalapril may be less effective in reducing blood pressure in patients with Negroid races with hypertension than in patients of other races, which may be due to lower activity of renin in the blood plasma of these patients.
    Effect on the ability to drive transp. cf. and fur:Care must be taken in time.use of Enalapril / Hydrochlorothiazide-Teva because of the possible development of adverse reactions (dizziness), which can adversely affect the ability to drive vehicles and perform potentially dangerous activities that require increased concentration and speed of psychomotor reactions.
    Form release / dosage:
    Tablets 10 mg + 25 mg.

    Packaging:
    For 10 tablets per blister of OPA / Al / PVC film and aluminum foil.

    By 2,3, 5,6,9 or 10 blisters together with instructions for use in a cardboard box.

    For 7 tablets per blister of OPA / Al / PVC film and aluminum foil.

    For 2.4 or 8 blisters together with instructions for use in a cardboard box.
    Storage conditions:Store at a temperature not exceeding 25 ° C. Keep out of the reach of children.
    Shelf life:
    2 years.
    Do not use after expiry date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001780
    Date of registration:23.07.2012
    Date of cancellation:2017-07-23
    The owner of the registration certificate:TEVA, LLC TEVA, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspTeva Teva Israel
    Information update date: & nbsp18.12.2015
    Illustrated instructions
      Instructions
      Up